Australia's most trusted
source of pharma news
Monday, 07 October 2024
Posted 1 October 2024 AM
It's time to dump the idea that any cancer can be described as 'good' or 'lucky', early breast cancer (eBC) patients have told a research project sponsored by Novartis.
Preliminary results from Project Shirley, run by Inherited Cancers Australia (ICA), formerly Pink Hope, reveal that despite eBC's high five-year survival rate, fear of recurrence is a pervasive concern for these patients and is associated with reduced quality of life that can persist long after treatment.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.